Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis

Human Pathology

Volumn 38, Issue 12, 2007, Pages 1760-1763

  Konoplev, Sergej ^a   Hsieh, Pin Pen ^b,c,d   Chang, Chung Che ^b,d   Medeiros, L Jeffrey ^a   Lin, Pei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chronic myelomonocytic leukemia; Chronic myeloproliferative disorders; Extramedullary hematopoiesis; JAK2; Spleen

Indexed keywords

BIOLOGICAL MARKER; JANUS KINASE 2; PARAFFIN;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER DIAGNOSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; DNA EXTRACTION; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; GENE MUTATION; HUMAN; MALE; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; MYELODYSPLASIA; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYCYTHEMIA VERA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; TISSUE FIXATION;

ADULT; AGED; BONE MARROW; CHROMOSOME ABERRATIONS; FEMALE; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN;

EID: 36549053576     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.04.004     Document Type: Article

References (15)

1. Ward H.P., and Block M.H. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 50 (1971) 357-420
2. Wolf B.C., and Neiman R.S. Hypothesis: splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. Hematol Pathol 1 (1987) 77-80
3. Wolf B.C., Luevano E., and Neiman R.S. Evidence to suggest that the human fetal spleen is not a hematopoietic organ. Am J Clin Pathol 80 (1983) 140-144
4. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
5. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
6. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
7. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
8. Szpurka H., Tiu R., Murugesan G., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 (2006) 2173-2181
9. Onciu M., Schlette E., Medeiros L.J., Abruzzo L.V., Keating M., and Lai R. Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol 116 (2001) 886-892
10. Olsen R.J., Tang Z., Farkas D.H., Bernard D.W., Zu Y., and Chang C.C. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med 130 (2006) 997-1003
11. Jelinek J., Oki Y., Gharibyan V., et al. JAK2 mutation 1849G(T) is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106 (2005) 3370-3373
12. Levine R.L., Belisle C., Wadleigh M., et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107 (2006) 4139-4141
13. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 105 (2005) 4187-4190
14. Tefferi A., and Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res 30 (2006) 739-744
15. O'Malley D.P., Kim Y.S., Perkins S.L., Baldridge L., Juliar B.E., and Orazi A. Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders. Mod Pathol 18 (2005) 1550-1561